Meeting of the COVID-19 Health Equity Task Force, 12954-12955 [2021-04605]
Download as PDF
12954
Federal Register / Vol. 86, No. 42 / Friday, March 5, 2021 / Notices
TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1
Total annual
responses
Average burden
per response
Total hours
Screener ..............................................................
Self-Administered Surveys ..................................
485,580
133,728
1
1
485,580
133,728
0.083 (5 minutes) ...........
0.33 (20 minutes) ...........
40,465
44,576
Total .............................................................
........................
........................
........................
........................................
85,041
1 There
are no capital costs or operating and maintenance costs associated with this collection of information.
Number of respondents to be included
in each new survey will vary,
depending on the nature of the material
or message being tested and the target
audience. Table 1 provides examples of
the types of activities that may be
administered and estimated burden
levels during the 3-year period. Time to
read, review, or complete the activity is
built into the ‘‘Average Burden per
Response’’ figures. Our estimated
burden for the information collection
reflects an overall increase of 60,000
hours and a corresponding increase of
461,808 responses. We attribute the
adjustment to an increase in the number
of new quantitative studies that are
anticipated underneath this information
collection during the next 3 years
(proposed extension).
Dated: March 1, 2021.
Lauren K. Roth,
Acting Principal Associate Commissioner for
Policy.
[FR Doc. 2021–04606 Filed 3–4–21; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2012–P–1189]
Canned Tuna Deviating From the
Standard of Identity; Amendment of
Temporary Marketing Permit
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA or we) is
amending StarKist Seafood Company’s
temporary permit to market test canned
tuna. The temporary permit is amended
to add three additional manufacturing
locations and to increase the amount of
test product. This amendment will
allow the applicant to continue to test
market the test product and collect data
on consumer acceptance of the test
product.
SUMMARY:
jbell on DSKJLSW7X2PROD with NOTICES
Number
of responses
per
respondent
Number
of
respondents
Activity
VerDate Sep<11>2014
20:30 Mar 04, 2021
Jkt 253001
FOR FURTHER INFORMATION CONTACT:
Marjan Morravej, Center for Food Safety
and Applied Nutrition (HFS–820), Food
and Drug Administration, 5001 Campus
Dr., College Park, MD 20740, 240–402–
2371.
SUPPLEMENTARY INFORMATION: In the
Federal Register of June 20, 2014 (79 FR
35362), we issued a notice announcing
that we had issued a temporary permit
to StarKist Seafood Company, 225 North
Shore Dr., Pittsburgh, PA 15212, to
market test products identified as
canned tuna products. The permit
allowed for the test product to be
manufactured at Galapesca S.A., Km.
12.5 Via A Duale, Guayaquil, Ecuador,
and StarKist Samoa Co., 368 Atu’u Rd.,
Pago Pago, American Samoa 96799. We
issued the permit to facilitate market
testing of products that deviate from the
requirements of the standard of identity
for canned tuna in 21 CFR 161.190,
which was issued under section 401 of
the Federal Food, Drug, and Cosmetic
Act (21 U.S.C. 341).
In the Federal Register of March 7,
2016 (81 FR 11813), we issued a notice
announcing that we were extending the
temporary market permit issued to
StarKist Seafood Company. The
extension allows the applicants to
continue to measure consumer
acceptance of the products and assess
the commercial feasibility of the
products, in support of a petition to
amend the standard of identity for
canned tuna. The new expiration date of
the permit will be either the effective
date of a final rule amending the
standard of identity for canned tuna that
may result from the petition or 30 days
after denial of the petition.
Under our regulations at 21 CFR
130.17(f), we are amending the
temporary permit issued to StarKist
Seafood Company, to allow the test
product to be manufactured at three
additional plants: Tropical Canning
(Thailand) Public Co., LTD., 1⁄1 M.2
T.Thungyai, Hatyai, Songkhla 90110,
Thailand; ISA Value Co., Ltd., 44/4
Moo1, Petchkasem Road, Yaicha,
Sampran, Nakornpathom 73110,
Thailand; and Tri-Marine (Solomon
PO 00000
Frm 00055
Fmt 4703
Sfmt 4703
Islands), Soltuna Ltd., 1 Tuna Dr., Noro,
Western Province, Solomon Islands. We
are also amending the temporary permit
to increase the amount of test product
to be market tested to 213,500,000
pounds (96,841,971 kilograms) in retail
cans of various sizes. All other
conditions and terms of this permit
remain the same.
Dated: February 26, 2021.
Lauren K. Roth,
Acting Principal Associate Commissioner for
Policy.
[FR Doc. 2021–04607 Filed 3–4–21; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Meeting of the COVID–19 Health Equity
Task Force
Office of the Assistant
Secretary for Health, Office of the
Secretary, Department of Health and
Human Services.
AGENCY:
ACTION:
Notice of meeting.
As required by the Federal
Advisory Committee Act, the U.S.
Department of Health and Human
Services (HHS) is hereby giving notice
that the COVID–19 Health Equity Task
Force (Task Force) will hold a virtual
meeting on March 26, 2021. The
purpose of this meeting is to discuss
equitable vaccine access and
acceptance. This meeting is open to the
public and will be live-streamed at
www.hhs.gov/live. Information about the
meeting will be posted on the HHS
Office of Minority Health website:
www.minorityhealth.hhs.gov/
healthequitytaskforce/ prior to the
meeting.
SUMMARY:
The Task Force meeting will be
held on Friday, March 26, 2021, from
approximately 12 p.m. to 3 p.m. ET
(times are tentative and subject to
change). The confirmed time and
agenda will be posted on the COVID–19
Health Equity Task Force website:
www.minorityhealth.hhs.gov/
DATES:
E:\FR\FM\05MRN1.SGM
05MRN1
Federal Register / Vol. 86, No. 42 / Friday, March 5, 2021 / Notices
healthequitytaskforce/ when this
information becomes available.
FOR FURTHER INFORMATION CONTACT:
Samuel Wu, Designated Federal Officer
for the Task Force; Office of Minority
Health, Department of Health and
Human Services, Tower Building, 1101
Wootton Parkway, Suite 100, Rockville,
Maryland 20852.
Phone: 240–453–6173; email:
COVID19HETF@hhs.gov.
jbell on DSKJLSW7X2PROD with NOTICES
SUPPLEMENTARY INFORMATION:
Background: COVID–19 Health Equity
Task Force (Task Force) was established
by Executive Order 13995, dated
January 21, 2021. The Task Force is
tasked with developing a set of
recommendations to the President,
through the Coordinator of the COVID–
19 Response and Counselor to the
President (COVID–19 Response
Coordinator) for mitigating the health
inequities caused or exacerbated by the
COVID–19 pandemic and for preventing
such inequities in the future. The Task
Force shall submit a final report to the
COVID–19 Response Coordinator
addressing any ongoing health
inequities faced by COVID–19 survivors
that may merit a public health response,
describing the factors that contributed to
disparities in COVID–19 outcomes, and
recommending actions to combat such
disparities in future pandemic
responses.
The meeting is open to the public and
will be live-streamed at www.hhs.gov/
live. A public comment session will be
held during the meeting. Pre-registration
is required to provide public comment
during the meeting. To pre-register to
attend or to provide public comment,
please send an email to
COVID19HETF@hhs.gov and include
your name, title, and organization by
close of business on Friday, March 19,
2021. Comments will be limited to no
more than three minutes per speaker
and should be pertinent to the meeting
discussion. Individuals are encouraged
to provide a written statement of any
public comment(s) for accurate minutetaking purposes. If you decide you
would like to provide public comment
but do not pre-register, you may submit
your written statement by emailing
COVID19HETF@hhs.gov no later than
close of business Thursday, April 1,
2021. Individuals who plan to attend
and need special assistance, such as
sign language interpretation or other
reasonable accommodations, should
contact: COVID19HETF@hhs.gov and
reference this meeting. Requests for
special accommodations should be
made at least ten (10) business days
prior to the meeting.
VerDate Sep<11>2014
20:30 Mar 04, 2021
Jkt 253001
12955
Dated: March 1, 2021.
Samuel Wu,
Designated Federal Officer, COVID–19 Health
Equity Task Force.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[FR Doc. 2021–04605 Filed 3–4–21; 8:45 am]
Center for Scientific Review; Notice of
Closed Meetings
BILLING CODE 4150–29–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Heart, Lung, and Blood
Institute; Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel;
Career Development Program to Promote
Diversity in Health Research (K01).
Date: April 1, 2021.
Time: 9:30 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6705
Rockledge Drive, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Lindsay M. Garvin, Ph.D.,
Scientific Review Officer, Office of Scientific
Review/DERA, National Heart, Lung, and
Blood Institute, National Institutes of Health,
6705 Rockledge Drive, Suite 208–Y,
Bethesda, MD 20892, (301) 827–7911,
lindsay.garvin@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.233, National Center for
Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung
Diseases Research; 93.839, Blood Diseases
and Resources Research, National Institutes
of Health, HHS)
Dated: March 1, 2021.
David W. Freeman,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–04523 Filed 3–4–21; 8:45 am]
BILLING CODE 4140–01–P
PO 00000
Frm 00056
Fmt 4703
Sfmt 4703
National Institutes of Health
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; RFA Panel:
Co-Occurring Conditions, Data Science, and
Clinical Trials Readiness in Down Syndrome.
Date: March 25, 2021.
Time: 9:00 a.m. to 1:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Maribeth Champoux,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3170,
MSC 7848, Bethesda, MD 20892, 301–594–
3163, champoum@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR 19–386
Environmental Risks for Psychiatric
Disorders: Biological Basis of
Pathophysiology.
Date: March 25, 2021.
Time: 3:00 p.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Julius Cinque, MS,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5186,
MSC 7846, Bethesda, MD 20892, (301) 435–
1252, cinquej@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Mechanisms of Stress, Emotion,
Health and Reward.
Date: March 26, 2021.
Time: 12:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Telephone Conference
Call).
Contact Person: Andrea B Kelly, Ph.D.,
Scientific Review Officer, Center for
E:\FR\FM\05MRN1.SGM
05MRN1
Agencies
[Federal Register Volume 86, Number 42 (Friday, March 5, 2021)]
[Notices]
[Pages 12954-12955]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-04605]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Meeting of the COVID-19 Health Equity Task Force
AGENCY: Office of the Assistant Secretary for Health, Office of the
Secretary, Department of Health and Human Services.
ACTION: Notice of meeting.
-----------------------------------------------------------------------
SUMMARY: As required by the Federal Advisory Committee Act, the U.S.
Department of Health and Human Services (HHS) is hereby giving notice
that the COVID-19 Health Equity Task Force (Task Force) will hold a
virtual meeting on March 26, 2021. The purpose of this meeting is to
discuss equitable vaccine access and acceptance. This meeting is open
to the public and will be live-streamed at www.hhs.gov/live.
Information about the meeting will be posted on the HHS Office of
Minority Health website: www.minorityhealth.hhs.gov/healthequitytaskforce/ prior to the meeting.
DATES: The Task Force meeting will be held on Friday, March 26, 2021,
from approximately 12 p.m. to 3 p.m. ET (times are tentative and
subject to change). The confirmed time and agenda will be posted on the
COVID-19 Health Equity Task Force website: www.minorityhealth.hhs.gov/
[[Page 12955]]
healthequitytaskforce/ when this information becomes available.
FOR FURTHER INFORMATION CONTACT: Samuel Wu, Designated Federal Officer
for the Task Force; Office of Minority Health, Department of Health and
Human Services, Tower Building, 1101 Wootton Parkway, Suite 100,
Rockville, Maryland 20852.
Phone: 240-453-6173; email: [email protected].
SUPPLEMENTARY INFORMATION: Background: COVID-19 Health Equity Task
Force (Task Force) was established by Executive Order 13995, dated
January 21, 2021. The Task Force is tasked with developing a set of
recommendations to the President, through the Coordinator of the COVID-
19 Response and Counselor to the President (COVID-19 Response
Coordinator) for mitigating the health inequities caused or exacerbated
by the COVID-19 pandemic and for preventing such inequities in the
future. The Task Force shall submit a final report to the COVID-19
Response Coordinator addressing any ongoing health inequities faced by
COVID-19 survivors that may merit a public health response, describing
the factors that contributed to disparities in COVID-19 outcomes, and
recommending actions to combat such disparities in future pandemic
responses.
The meeting is open to the public and will be live-streamed at
www.hhs.gov/live. A public comment session will be held during the
meeting. Pre-registration is required to provide public comment during
the meeting. To pre-register to attend or to provide public comment,
please send an email to [email protected] and include your name,
title, and organization by close of business on Friday, March 19, 2021.
Comments will be limited to no more than three minutes per speaker and
should be pertinent to the meeting discussion. Individuals are
encouraged to provide a written statement of any public comment(s) for
accurate minute-taking purposes. If you decide you would like to
provide public comment but do not pre-register, you may submit your
written statement by emailing [email protected] no later than close
of business Thursday, April 1, 2021. Individuals who plan to attend and
need special assistance, such as sign language interpretation or other
reasonable accommodations, should contact: [email protected] and
reference this meeting. Requests for special accommodations should be
made at least ten (10) business days prior to the meeting.
Dated: March 1, 2021.
Samuel Wu,
Designated Federal Officer, COVID-19 Health Equity Task Force.
[FR Doc. 2021-04605 Filed 3-4-21; 8:45 am]
BILLING CODE 4150-29-P